---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-329003"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2021-11-15T23:59:59+00:00"
generated_at: "2026-06-28T08:22:35.191234+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Acumen Q3 loss $3.9M, cash $229.9M; ACU193 Phase 1 trial enrolling

## Summary
- Net loss $3.9M (Q3), $92.3M (9M) including $80.3M non-cash fair-value charges from preferred stock and warrant liabilities.
- Cash and marketable securities $229.9M at Sep 30, 2021 (vs. $43.8M at Dec 2020); IPO net proceeds $168.6M in July 2021.
- R&D expenses $1.8M (Q3), G&A $2.1M; loss from operations $3.9M.
- INTERCEPT-AD Phase 1 trial of ACU193 (anti-AβO antibody) dosed first patient; sentinel safety review passed.
- Topline data expected by end of 2022; COVID-19 Delta variant delayed site activation but recruitment ongoing.

## SEC filing metadata
- accession: 0001193125-21-329003
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2021-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000119312521329003/0001193125-21-329003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000119312521329003/d255444d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-329003
- JSON: https://secwatch.observer/filing/0001193125-21-329003.json
- Plain text: https://secwatch.observer/filing/0001193125-21-329003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.